Ocugen Inc Equity-NMS: OCGN

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$1.5

52W high :

$6.5

1Y :

-81.28%

5Y :

-26.34%

Shares O/S :

218.89 M

Market cap :

306.44 M

What is the share price of Ocugen Inc today?

Ocugen Inc (OCGN) share price as of October 11, 2022, is $1.64. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Ocugen Inc?

Yes, Indian Investors can invest in the Ocugen Inc (OCGN) Share by opening an international trading account with Angel One.

How can I purchase Ocugen Inc shares in India?

Purchasing Ocugen Inc (OCGN) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Ocugen Inc (OCGN) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Ocugen Inc?

Yes, you can purchase fractional shares of Ocugen Inc (OCGN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Ocugen Inc?

The market capitalization of Ocugen Inc on December 6, 2022, is $355.17 M.

In which sector Ocugen Inc belongs?

Ocugen Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Ocugen Inc stocks?

In order to invest in Ocugen Inc (OCGN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.